Supplementary Methods from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

Supplementary Methods</p

Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

Supplementary figures</p

Supplementary Tables from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

Supplementary tables</p

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table S2 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Major pathways involving high-comboscore candidates</p

Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Supplementary Figure S1: Representative flow strategies for detection of apoptotic cells. Supplementary Figure S2: The top 20 candidates with the highest comboscores from the ORF screen. Supplementary Figure S3: MEX3B expression is higher in non-responders than in responders to anti-PD-1 immunotherapy Supplementary Figure S4: Knockdown of MEX3B increases the susceptibility of tumor cells to T cell-mediated cytotoxicity Supplementary Figure S5: Overexpression of HLA-A2 in 2549 melanoma cells results in similar IFNɣ release in MART-1-specific TILs incubated with melanoma cells overexpressing GFP-MEX3B or GFP control Supplementary Figure S6: Overexpression of MEX3B in 2549 melanoma cells decreases surface HLA-A31 expression Supplementary Figure S7: Overexpression of MEX3B in 2549 melanoma cells does not alter HLA-B or HLA-C expression Supplementary Figure S8: Alteration of expression of antigen processing and presentation machinery components upon MEX3B overexpression Supplementary Figure S9: A schematic graph representing transcription factors that may regulate MEX3B expression.</p